↑ トップへ ← 戻る

 Drug(薬物リスト) DrugBank | All Description Patterns

   e.g. "Sirolimus", "アダリムマブ"    Synonyms (Drugs) were also searched for.

A B C D E F G H  I  J K L M N O P Q R S T U V W X Y Z other

113 / 1,666 drugs found* Show info (disease name, etc.) on mouse-over.
 No.   DrugBank   薬物名(臨床試験情報から抽出)   KEGG DRUG  KEGG GENES  KEGG PATHWAY   指定難病告示番号
 1   Acetaminophen  8件: Acetaminophen; Acetaminophen tab 650mg; Acetaminophen tablets; Acetaminophen/paracetamol; Oxycodone/acetaminophen; Paracetamol (acetaminophen); Tramadol /acetaminophen; Tramadol hydrochloride + acetaminophen;   D00217   2件: PTGS1, PTGS2   21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway   13件:
3,
6,
13,
34,
35,
46,
49,
51,
70,
86,
231,
256,
271
 2   Acetate  76件: 11c acetate; 11c-acetate; 20mg/0.5ml glatiramer acetate; 40 mg glatiramer acetate; [n-trans-3-hexenoyl] human growth hormone releasing factor (1-44) acetate; Abiraterone acetate; Acetate; Bazedoxifene acetate; Betamethasone sodium phosphate/betamethasone acetate (celestone® soluspan®), 30 mg im once a day for four days; Caspofungin acetate; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Cortisone acetate; Cosyntropin acetate; Cyclophosphamide/glatiramer acetate; Delmitide acetate; Depot leuprolide acetate 3.75 mg; Desmopressin acetate; Desmopressin acetate trihydrate; Dirucotide acetate; Experimental glatiramer acetate; Flecainide acetate; Glatiramer acetate; Glatiramer acetate (copaxone®); Glatiramer acetate (db); Glatiramer acetate (ga); Glatiramer acetate (ga) 40 mg; Glatiramer acetate (ol); Glatiramer acetate 150mg enteric coated tablets; Glatiramer acetate 150mg enteric-coated (gastro-resistant) tablets; Glatiramer acetate 20 mg; Glatiramer acetate 20 mg, with mitoxantrone; Glatiramer acetate 20 mg/0.5 ml; Glatiramer acetate 40 mg; Glatiramer acetate injection with oral cetirizine hydrochloride; Glatiramer acetate with minocycline; Glatiramer acetate, (copaxone®); Glatiramer acetate, ifn-beta 1a (im), ifn-beta 1a (subcutaneous), and ifn-beta 1b; Glatiramer acetate, n-acetylcysteine; Gonadorelin acetate and triptorelin acetate; Human interferon beta-1a and glatiramer acetate; Hydrocortisone sodium acetate; L-lysyl-d-prolyl-l-threonine acetate; Lanreotide acetate; Leuprolide acetate (la); Leuprolide acetate 11.25 mg; Leuprolide acetate 3 month depot; Leuprolide acetate 30 mg; Leuprolide acetate 45 mg; Leuprolide acetate depot; Leuprorelin acetate; Leuprorelin acetate 3.75mg injection; Loestrin (norethindrone acetate and ethinyl estradiol); Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol); Luphere depot 3.75mg(leuprolide acetate 3.75mg); Lupron (leuprolide acetate); Macimorelin acetate; Megestrol acetate; Megestrol acetate tablet; Nomegestrol acetate; Phosphate and betamethasone acetate, 2 ml.; Plovamer acetate; Prednisolone acetate; Prednisone acetate; Prednisone acetate tablets; Sodium acetate; Sodium-[o-[(2,6-dichlorophenyl)-amino]-phenyl]-acetate; Sotrastaurin (inn) acetate; Tetracosactide acetate; Tocopherol acetate; Tocopheryl acetate; Triptorelin acetate and gonadorelin acetate; Ulipristal acetate; Zinc acetate; Zinc acetate (20mg/d); Zinc acetate dihydrate; Zuretinol acetate;   -   -   -   40件:
1,
2,
6,
10,
13,
35,
40,
46,
49,
51,
60,
64,
70,
71,
73,
75,
76,
78,
81,
83,
85,
86,
88,
90,
96,
97,
113,
145,
156,
162,
171,
206,
222,
224,
225,
235,
265,
288,
298,
299
 3   Acetic acid C-11  -  -   -   -   3件:
13,
86,
88
 4   Acetylsalicylic acid  2件: Acetylsalicylic acid; Acetylsalicylic acid at 1st visit,;   D00109   2件: PTGS1, PTGS2   21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway   10件:
13,
22,
34,
46,
49,
51,
86,
113,
158,
231
 5   Activated charcoal  -  D03251   -   -   8件:
6,
13,
46,
85,
86,
96,
97,
298
 6   Ambrisentan  8件: Ambrisentan; Ambrisentan - high dose; Ambrisentan - low dose; Ambrisentan 5 mg; Ambrisentan 5 mg film-coated tablets; Ambrisentan plus spironolactone; Bosentan, ambrisentan; Tadalafil and ambrisentan upfront combination therapy;   D07077   1件: EDNRA   7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   6件:
51,
84,
85,
86,
88,
211
 7   Anakinra  8件: Anakinra; Anakinra (kineret®); Anakinra (r-methuil-1ra); Anakinra / kineret; Anakinra and peg stnf-r1; Kineret® (anakinra); Kineret® or anakinra; Response to anakinra associated with methotrexate;   D02934   2件: IL1R1, IL1R2   15件: Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer   17件:
2,
13,
15,
19,
37,
41,
46,
49,
50,
56,
65,
84,
86,
106,
107,
266,
299
 8   Anastrozole  2件: Anastrozole; Arimidex (anastrozole);   D00960   1件: CYP19A1   3件: Metabolic pathways, Ovarian steroidogenesis, Steroid hormone biosynthesis   3件:
78,
86,
193
 9   Angiotensin II  2件: Angiotensin ii; Symptomatic treatment (converting enzyme inhibitor, angiotensin ii, anti-renin, aldosterone antagonist diuretic, beta blocker, calcium inhibitor, statin);   D00150
 D02014 
 2件: AGTR1, AGTR2   14件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway   7件:
17,
19,
46,
66,
86,
222,
224
 10   Apabetalone  1件: Apabetalone;   D11131   -   -   1件:
86
 11   Ascorbic acid  4件: 2l polyethylene glycol/ascorbic acid; Ascorbic acid; Ascorbic acid (vitamin c); Ascorbic acid vit c;   D00018   -   -   13件:
10,
13,
49,
62,
86,
96,
97,
192,
206,
211,
212,
254,
284
 12   Aviptadil  2件: Aviptadil; Aviptadil, 66 microgram/ml;   -   -   -   4件:
49,
51,
85,
86
 13   Bardoxolone  4件: Bardoxolone; Bardoxolone methyl; Bardoxolone methyl capsules; Bardoxolone methyl oral capsule;   D09584   -   -   7件:
66,
67,
84,
85,
86,
218,
222
 14   Bardoxolone methyl  3件: Bardoxolone methyl; Bardoxolone methyl capsules; Bardoxolone methyl oral capsule;   D09585   -   -   7件:
66,
67,
84,
85,
86,
218,
222
 15   Benzbromarone  1件: Benzbromarone;   D01056   -   -   1件:
86
 16   Beraprost  4件: Beraprost; Beraprost sodium; Beraprost sodium 314d modified release tablets; Beraprost sodium modified release;   D02720   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86
 17   Bevacizumab  4件: Bevacizumab; Bevacizumab (avastin) and imatinib mesylate (gleevec); Bevacizumab (genitical recombination); Submucosal bevacizumab;   D06409   1件: VEGFA   21件: AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway   9件:
13,
34,
85,
86,
87,
89,
227,
280,
331
 18   Bisoprolol  2件: Bisoprolol; Bisoprolol fumarate;   D00634
 D02342 
 1件: ADRB1   10件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway   3件:
67,
86,
113
 19   Bosentan  14件: Bosentan; Bosentan (tracleer); Bosentan 125 mg; Bosentan 62.5 mg; Bosentan administration; Bosentan and sildenafil; Bosentan group; Bosentan monohydrat; Bosentan monohydrate; Bosentan mylan; Bosentan, ambrisentan; Era and pde-5i (sildenafil, tadalafil, bosentan, macitentan); Sildenafil 20mg and bosentan 62.5mg; Sildenafil singly or in association with bosentan;   D01227
 D07538 
 2件: EDNRA, EDNRB   9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   10件:
13,
41,
47,
51,
84,
85,
86,
88,
210,
211
 20   CXA-10  3件: 150mg cxa-10; 75mg cxa-10; Cxa-10;   -   -   -   2件:
86,
222
 21   Capsaicin  4件: Capsaicin; Capsaicin challenge; Capsaicin vapor; Qutenza (8% capsaicin);   D00250   1件: TRPV1   2件: Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction   6件:
2,
6,
19,
86,
113,
226
 22   Captopril  2件: Captopril; Spironolactone captopril carvedilol;   D00251   1件: ACE   4件: Chagas disease (American trypanosomiasis), Hypertrophic cardiomyopathy (HCM), Renin secretion, Renin-angiotensin system   2件:
17,
86
 23   Carbon monoxide  2件: Carbon monoxide; Inhaled carbon monoxide;   D09706   -   -   3件:
85,
86,
298
 24   Carvedilol  2件: Carvedilol; Spironolactone captopril carvedilol;   D00255
 D03415 
 5件: ADRA1A, ADRA1B, ADRA1D, ADRB1, ADRB2   12件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   4件:
6,
57,
86,
113
 25   Cetuximab  1件: Cetuximab;   D03455   1件: EGFR   45件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Endometrial cancer, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH signaling pathway, HIF-1 signaling pathway, Hepatitis C, Hepatocellular carcinoma, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, Non-small cell lung cancer, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis   5件:
34,
51,
86,
89,
331
 26   Chlorhexidine  5件: 2% chlorhexidine solution wipes; 4% chlorhexidine gluconate liquid skin cleanser; Chlorhexidine; Chlorhexidine gluconate; Chlorhexidine gluconate oral rinse;   D00858
 D01345
 D03463
 D07668 
 -   -   2件:
86,
299
 27   Cicletanine  1件: Cicletanine;   D03487   -   -   1件:
86
 28   Clopidogrel  1件: Clopidogrel;   D00769
 D07729
 D10823
 D10824 
 1件: P2RY12   1件: Platelet activation   2件:
49,
86
 29   Conivaptan  2件: Conivaptan; Spironolactone and conivaptan;   D01236
 D07748 
 2件: AVPR1A, AVPR2   5件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vascular smooth muscle contraction, Vasopressin-regulated water reabsorption   1件:
86
 30   Cyanocobalamin  -  D00166
 D03615
 D03616
 D03617 
 -   -   12件:
6,
13,
49,
62,
86,
96,
97,
201,
229,
254,
284,
299
 31   D-glucose  3件: 2-deoxy-2 [f-18] fluoro-2-d-glucose; [18f]fluoro-2-deoxy-2-d-glucose; D-glucose;   D00009   -   -   6件:
6,
13,
49,
86,
88,
299
 32   Dichloroacetic acid  -  -   -   -   1件:
86
 33   Diltiazem  3件: Diltiazem; Diltiazem hydrochloride; Dofetilide and diltiazem;   D00616
 D03830
 D07845 
 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S   34件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   3件:
58,
86,
130
 34   Dimethyl fumarate  4件: Dimethyl fumarate; Dimethyl fumarate (dmf); Dimethyl fumarate [dmf]; Tecifdera (dimethyl fumarate);   D03846   1件: KEAP1   4件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Pathways in cancer, Ubiquitin mediated proteolysis   5件:
13,
46,
49,
51,
86
 35   Diphenhydramine  1件: Diphenhydramine;   D00300
 D00669
 D02419
 D03285
 D03360
 D03854 
 1件: HRH1   3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction   5件:
49,
51,
70,
86,
256
 36   Docusate  -  D00305   -   -   7件:
13,
62,
86,
96,
97,
254,
284
 37   Elafin  1件: Elafin;   -   -   -   1件:
86
 38   Epicatechin  3件: (+)- epicatechin; (-)-epicatechin; Epicatechin;   -   -   -   2件:
86,
113
 39   Epinephrine  4件: Bupivacaine/epinephrine/dexamethasone; Epinephrine; Lap tap bupivacaine/epinephrine; Us tap bupivacaine/epinephrine;   D00095
 D00996
 D02149 
 9件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3   13件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   9件:
6,
13,
46,
86,
96,
168,
226,
231,
256
 40   Epoprostenol  7件: Act-385781a (actelion epoprostenol); Current marketed flolan (epoprostenol sodium); Epoprostenol; Epoprostenol for injection; Epoprostenol sodium; Epoprostenol-actelion; New thermo stable formulation of epoprostenol sodium;   D00106
 D01337 
 1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86
 41   Esomeprazole  3件: Esomeprazole; Esomeprazole 20 mg; Nexium (esomeprazole magnesium);   D01984
 D04056
 D07917
 D09339 
 2件: ATP4A, ATP4B   4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation   6件:
6,
46,
86,
98,
298,
299
 42   Ethanol  7件: Andrographis paniculata (ethanol extract); Ethanol; Ethanol (96 per cent); Ethanol 96% gel; Ethanol 98% solution; Ethanol bp; Ethanol gel;   D00068
 D02798
 D04855
 D06542 
 -   -   49件:
2,
11,
13,
14,
26,
35,
40,
41,
42,
43,
44,
45,
46,
49,
50,
51,
53,
58,
61,
63,
64,
65,
66,
81,
84,
85,
86,
88,
95,
96,
97,
113,
145,
162,
164,
222,
224,
228,
251,
279,
280,
283,
284,
285,
288,
298,
299,
300,
331
 43   Famotidine  2件: Famotidine; Famotidine 20 mg;   D00318   1件: HRH2   3件: Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction   3件:
6,
46,
86
 44   Ferric carboxymaltose  2件: Ferric carboxymaltose; Intravenous administration of ferric carboxymaltose;   D08920   -   -   4件:
86,
96,
97,
299
 45   Fluoxetine  4件: Amitriptyline, fluoxetine and tramadol alone (control group); Fluoxetine; Fluoxetine hydrochloride; Sc recombinant growth hormone + amitriptyline, fluoxetine and tramadol (treated group);   D00326
 D00823 
 1件: SLC6A4   2件: Serotonergic synapse, Synaptic vesicle cycle   6件:
13,
17,
78,
86,
179,
206
 46   Folic acid  5件: Folic acid; Folic acid or folate; Folic acid, vitamin b6, vitamin b12; Methotrexate and folic acid; Rituximab, mtx, folic acid;   D00070   -   -   11件:
6,
13,
46,
49,
62,
84,
86,
96,
97,
254,
284
 47   Fulvestrant  1件: Fulvestrant;   D01161   2件: ESR1, ESR2   9件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway   1件:
86
 48   Gadobenic acid  -  D04283
 D08018 
 -   -   3件:
13,
86,
88
 49   Glycine  4件: Flolan tm and glycine diluent; Flolan™ and glycine diluent; Glycine; Glycine buffer;   D00011   -   -   4件:
35,
86,
226,
299
 50   Hydroxyurea  1件: Hydroxyurea;   D00341   1件: RRM2   6件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism, p53 signaling pathway   8件:
3,
13,
19,
20,
65,
85,
86,
284
 51   Ifetroban  2件: Ifetroban; Oral ifetroban;   D04500   1件: TBXA2R   3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Platelet activation   3件:
51,
86,
113
 52   Iloprost  21件: Aerosolized iloprost; Commercial ventavis® (iloprost); Iloprost; Iloprost (5 µg); Iloprost (ventavis bayq6256); Iloprost (ventavis inhaled, bayq6256); Iloprost (ventavis, bayq 6256); Iloprost (ventavis, bayq6256); Iloprost (ventavis®); Iloprost inhalation solution (ventavis); Iloprost injection, for intravenous use; Iloprost low dose; Iloprost pd-15; Iloprost pd-6; Iloprost sale di trometamolo; Iloprost therapy up to 2 ng/kg x min; Iloprost trometamol; Iloprost,(ventavis, bayq6256); Inhaled iloprost (ventavis, bayq6256); Ventavis (iloprost, bayq6256); Ventavis(iloprost);   D02721   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   4件:
51,
84,
85,
86
 53   Imatinib  6件: Bevacizumab (avastin) and imatinib mesylate (gleevec); Imatinib; Imatinib mesilate; Imatinib mesylate; Imatinib mesylate (gleevec); Imatinib mesylate 400mg capsule;   D01441
 D08066 
 3件: ABL1, KIT, PDGFRA   32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis   11件:
13,
28,
34,
35,
46,
51,
85,
86,
87,
89,
162
 54   Ipratropium  4件: Ipratropium; Ipratropium bromide (drug); Nebulized combination ipratropium bromide with salbutamol; Nebulized ipratropium bromide;   D02212   5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5   11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway   2件:
6,
86
 55   Iron  14件: Injection of iron; Iron; Iron chelating agents; Iron dextran; Iron oxide; Iron sucrose; Iron sulphate; Iron sulphate 200mg coated tablets; Iron supplement; Iron supplement 300-600 mg/day; Iron(iii)- hydroxide dextran complex; Oral iron; Ultra small particles of iron oxide (uspio); Ultrasmall particles of iron oxide;   -   -   -   7件:
13,
62,
86,
96,
97,
254,
284
 56   L-Citrulline  5件: 750 mg metformin and 7.5 g l-citrulline daily p.o.; L-citrulline; L-citrulline and metformin & l-citrulline; L-citrulline malate; Metformin and metformin & l-citrulline;   D07706   -   -   2件:
86,
113
 57   L-Threonine  2件: L-lysyl-d-prolyl-l-threonine acetate; L-threonine;   D00041   -   -   3件:
86,
96,
97
 58   Lidocaine  8件: 5% lidocaine/5 mg/ml estradiol compound cream; Alkalinized lidocaine-heparin; Bladder instillation with heparin/ lidocaine; Lidocaine; Lidocaine injection 2%; Lidocaine patch 5%; Lidocaine releasing intravesical system - liris®; Local anesthesia (lidocaine hydrochloride);   D00358
 D02086
 D08127 
 5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A   3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction   10件:
6,
13,
46,
84,
86,
97,
168,
226,
231,
256
 59   Lisuride  5件: Lisuride; Lisuride hydrogenmaleate; Lisuride transdermal system; Lisuride tts 10cm²; Lisuride tts 20cm²;   D01462
 D08132 
 3件: DRD2, DRD3, DRD4   8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway   2件:
6,
86
 60   Macitentan  8件: Act-064992 (macitentan); Era and pde-5i (sildenafil, tadalafil, bosentan, macitentan); Fdc macitentan/tadalafil; Macitentan; Macitentan 10 mg; Macitentan 10 mg tablet, once daily.; Macitentan group; Opsumit (macitentan);   D10135   2件: EDNRA, EDNRB   9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   5件:
51,
85,
86,
88,
210
 61   Medical air  4件: Medical air; Medical air (sham o2); Medical air vs oxygen; Sham o2 (medical air);   -   -   -   3件:
85,
86,
193
 62   Mercaptopurine  8件: 6 mercaptopurine; 6-mercaptopurine; Azathioprine (aza) or 6-mercaptopurine (6-mp); Azathioprine or 6-mercaptopurine; Delayed release 6 mercaptopurine; Mercaptopurine; Mercaptopurine (puri-nethol); Products containing azathioprine or 6-mercaptopurine;   D00161
 D04931 
 1件: HPRT1   3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism   5件:
86,
94,
96,
97,
164
 63   Metformin  12件: 750 mg metformin and 7.5 g l-citrulline daily p.o.; Glucophage (metformin); L-citrulline and metformin & l-citrulline; Metformin; Metformin (generic); Metformin 500mg; Metformin and metformin & l-citrulline; Metformin hcl; Metformin hydrochloride; Metformin/cp-690,550; Pioglitazone or metformin; Sitagliptin and metformin;   D00944
 D04966 
 2件: PRKAA1, PRKAA2   19件: AMPK signaling pathway, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy (HCM), Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease (NAFLD), Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway   17件:
6,
13,
46,
49,
67,
75,
77,
81,
86,
113,
158,
206,
225,
233,
265,
285,
299
 64   Methylprednisolone  29件: Administration of rituximab and methylprednisolone; Corticosteroid treatment (methylprednisolone or prednisolone); Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Infliximab, methylprednisolone, methotrexate; Intravenous (i.v.) methylprednisolone 1000 mg, total 9; Intravenous methylprednisolone; Iv methylprednisolone; Iv methylprednisolone (steroids); Megadose oral methylprednisolone; Methotrexate + methylprednisolone; Methylprednisolone; Methylprednisolone (drug); Methylprednisolone (mp); Methylprednisolone (mp) or prednisone (pred); Methylprednisolone (or other glucocorticoid); Methylprednisolone bolus iv 15 mg/kg/d for 3 days.; Methylprednisolone hemisuccinate; Methylprednisolone iv; Methylprednisolone mylan générique; Methylprednisolone or budesonide; Methylprednisolone or prednisolone; Methylprednisolone pulse; Methylprednisolone sodium hemisuccinate; Methylprednisolone sodium succinate; Methylprednisolone(intravenously in the 1st-2nd-3rd month ); Methylprednisolone(intravenously in the 1st-3rd-5th month); Oral 5-asa+/-topical 5-asa+iv corticosteroids / po methylprednisolone; Prednisone (and methylprednisolone); Prednisone, methylprednisolone,cyclophosphamides;   D00407
 D00751
 D00979
 D05000
 D05001
 D05002 
 1件: NR3C1   1件: Neuroactive ligand-receptor interaction   36件:
2,
13,
25,
26,
35,
38,
39,
40,
41,
42,
43,
45,
46,
49,
50,
51,
60,
63,
64,
65,
66,
83,
84,
86,
96,
97,
145,
164,
220,
222,
224,
271,
283,
284,
285,
296
 65   Morphine  6件: Intraarticular morphine; Morphine; Morphine hexal; Morphine pca; Morphine sulfate; Morphine sulphate in intrasite gel;   D00842
 D02271
 D08233 
 1件: OPRM1   3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction   4件:
36,
46,
70,
86
 66   Moxifloxacin  5件: Avelox- moxifloxacin; Moxifloxacin; Moxifloxacin 400 mg; Moxifloxacin hydrochloride; Moxifloxacin infusion;   D00874
 D08237 
 -   -   8件:
2,
6,
46,
49,
85,
86,
240,
299
 67   Nicardipine  1件: Nicardipine;   D00617
 D08270 
 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S   34件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   2件:
70,
86
 68   Nilotinib  8件: Cohort 1:nilotinib oral capsules (150mg or 300mg); Cohort 2: nilotinib oral capsules (dose to be determined from cohort 1); Nilotinib; Nilotinib (tasigna); Nilotinib 150 mg; Nilotinib 150mg oral capsule [tasigna]; Nilotinib 300mg oral capsule [tasigna]; Nilotinib hydrochloride monohydrate;   D08953   4件: ABL1, KIT, PDGFRA, PDGFRB   33件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis   5件:
6,
8,
34,
51,
86
 69   Nitric Oxide  11件: Inhaled nitric oxide; Inhaled nitric oxide & inopulse delivery; Inhaled nitric oxide - 30 mcg/kg ibw/hr; Inhaled nitric oxide 5,10,15 mcg/kg ibw/hr; Inhaled nitric oxide 75 mcg/kg ibw/hr; Nitric oxide; Nitric oxide 160 ppm; Nitric oxide for inhalation; Nitric oxide generated by the geno nitrosyl delivery system; Nitric oxide plus oxygen; Nitric oxide supplement;   D00074   -   -   7件:
46,
85,
86,
98,
251,
294,
299
 70   Nitrite  9件: 120 mg sodium nitrite inhalation solution; 15 mg sodium nitrite inhalation solution; 25% mtd sodium nitrite inhalation solution; 45 mg sodium nitrite inhalation solution; 90 mg sodium nitrite inhalation solution; Air001 (sodium nitrite inhalation solution); Nitrite; Sodium nitrite; Sodium nitrite inhalation solution;   -   -   -   2件:
86,
299
 71   Olaparib  1件: Olaparib;   D09730   3件: PARP1, PARP2, PARP3   4件: Apoptosis, Base excision repair, NF-kappa B signaling pathway, Necroptosis   1件:
86
 72   Oxygen  9件: Continuous oxygen; Helium / oxygen mixed gas inhalation therapy; Medical air vs oxygen; Medical grade oxygen; Nitric oxide plus oxygen; Oxygen; Oxygen 40 %; Oxygen supplementation; Perfluorinated gas/oxygen mixture;   D00003   -   -   18件:
5,
6,
17,
46,
49,
70,
84,
85,
86,
88,
90,
96,
97,
193,
211,
226,
299,
330
 73   PF-00489791  1件: Pf-00489791;   -   -   -   1件:
86
 74   Pioglitazone  6件: Actos (pioglitazone); Pioglitazone; Pioglitazone 15 mg; Pioglitazone and tretinoin; Pioglitazone or metformin; Tretinoin and pioglitazone hcl;   D00945
 D08378 
 1件: PPARG   9件: AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer   17件:
2,
6,
13,
15,
20,
46,
49,
65,
67,
78,
81,
86,
96,
229,
265,
298,
299
 75   Prasterone  2件: Prasterone; Prasterone (gl701);   D08409   3件: AR, ESR1, ESR2   11件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway   6件:
49,
53,
83,
86,
96,
113
 76   Prednisone  57件: 0 mg prednisone; 5 mg prednisone; 5-aminosalicylic acid(5-asa) and/or prednisone; 5-asa, prednisone, azathioprine or remicade; Azathioprine/prednisone; Chinese herb prescription granule plus prednisone; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Corticosteroids (prednisone or prednisolone); Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Cyclophosphamide-prednisone-azathioprine; Glucocorticoid (prednisone or prednisolone); Granulocyte-colony stimulating factor (g-csf) and prednisone; Hormone (prednisone); Hydroxychloroquine + prednisone; Leflunomide 20 mg+prednisone 0.5mg/kg/d; Methylprednisolone (mp) or prednisone (pred); Mycophenolate mofetil plus lower dose of prednisone; Oral prednisone; Oral prednisone 5mg; Over encapsulated prednisone; Prednisone; Prednisone (and methylprednisolone); Prednisone + inhibace/cozaar; Prednisone - azathioprine; Prednisone 0,5 mg/kg orally on alternate days; Prednisone 15 mg; Prednisone 5 mg; Prednisone 7.5 mg; Prednisone acetate; Prednisone acetate tablets; Prednisone alone; Prednisone and cyclophosphamide; Prednisone and mycophenolate mofetil; Prednisone and ustekinumab treatment; Prednisone arrow 20mg; Prednisone arrow 5 mg; Prednisone capsules; Prednisone discontinuation; Prednisone in full dose; Prednisone or prednisolone; Prednisone plus cyclophosphamide; Prednisone tablets usp, 1 mg; Prednisone tablets usp, 2.5 mg; Prednisone tablets usp, 5 mg; Prednisone tablets, usp; Prednisone therapy and pharmacokinetic; Prednisone treatment; Prednisone, cyclophosphamide; Prednisone, fk506, mmf; Prednisone, methylprednisolone,cyclophosphamides; Prednisone/prednisolone; Rayos (delayed-release prednisone); Sotatercept with prednisone boost; Tacrolimus combined with prednisone; Thalidomide, cyclophosphamide and prednisone; Treatment systemic therapy (prednisone); Treatment with systemic therapy (prednisone);   D00473   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   44件:
2,
11,
13,
14,
26,
35,
40,
41,
42,
43,
44,
45,
46,
49,
50,
51,
53,
61,
63,
64,
65,
66,
81,
84,
85,
86,
95,
96,
97,
113,
145,
162,
164,
222,
224,
228,
251,
283,
284,
285,
288,
299,
300,
331
 77   Ralinepag  1件: Ralinepag;   D10725   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86
 78   Ranolazine  7件: Ranolazine; Ranolazine 1000 mg; Ranolazine 1000 mg pr tablets; Ranolazine 500 mg; Ranolazine 500 mg pr tablets; Ranolazine 750 mg pr tablets; Ranolazine pr (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die;   D05700
 D05701 
 -   -   6件:
2,
58,
86,
113,
114,
130
 79   Rifampicin  1件: Rifampicin;   D00211   -   -   7件:
6,
13,
17,
46,
84,
86,
299
 80   Riociguat  12件: Adempas (riociguat, bay63-2521); Riociguat; Riociguat (adempas, bay63-2521); Riociguat (bay63-2521); Riociguat coated tablet 0.5 mg; Riociguat coated tablet 1.0 mg; Riociguat coated tablet 1.5 mg; Riociguat coated tablet 2.0 mg; Riociguat coated tablet 2.5 mg; Riociguat granules 0.3% for oral application; Riociguat oral product; Riociguat pill;   D09572   3件: GUCY1A1, GUCY1A2, GUCY1B1   11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway   6件:
51,
84,
86,
88,
225,
299
 81   Ritonavir  9件: Atazanavir (atv) + ritonavir (rtv), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (nrtis); Atazanavir/ritonavir; Lopinavir / ritonavir; Lopinavir/ritonavir; Lopinavir/ritonavir + nevirapine; Lopinavir/ritonavir + zidovudine + lamivudine; Ritonavir; Ritonavir (norvir); Saquinavir and ritonavir;   D00427   -   -   5件:
2,
86,
130,
265,
299
 82   Rituximab  52件: Abatacept, rituximab or tocilizumab; Abp 798 - biosimilar to rituximab; Administration of rituximab and methylprednisolone; Alemtuzumab and rituximab; Alemtuzumab, rituximab; Bendamustine, rituximab; Combination of protein a immunoadsorption, rituximab, dexamethasone plus azathioprine; Combined plasma exchange (pex), rituximab, and corticosteroids; Dexamethasone and rituximab; Experimental (non immunosuppressive symptomatic treatment (nist) and rituximab); Gp2013 - a proposed biosimilar rituximab; Idec-c2b8 (rituximab); Immunosuppressive treatment (eg, rituximab); Individualized dose of rituximab; Intravenous rituximab; Mabthera (rituximab); Mabthera or biosimilar rituximab; Mabthera or biosimilar rituximab product; Mabthera® (rituximab); Originator rituximab - rituxan ® or mabthera ®; Rhtpo in combination with rituximab; Rituxan (inn: rituximab), brand name in the united states; Rituxan (rituximab); Rituxan® (rituximab); Rituximab; Rituximab (anti-cd20); Rituximab (arm a); Rituximab (arm b); Rituximab (mabthera® or rituxan®).; Rituximab (mabthera®); Rituximab (rituxan); Rituximab (rtx) and azathioprine (aza); Rituximab - mabthera; Rituximab 1g iv; Rituximab [mabthera/rituxan]; Rituximab [mabthera]; Rituximab and cyclophosphamide iv; Rituximab combined with omalizumab; Rituximab infusion; Rituximab it; Rituximab iv; Rituximab mabthera; Rituximab or rituximab hyaluronidase human; Rituximab, mtx, folic acid; Rituximab, observational study amon patients with active ra; Rituximab-eu+ rituximab-pfizer x 2 courses; Rituximab-pfizer (pf-05280586) x 3 courses; Rituximab-us + rituximab-pfizer x 2 courses; Rituximab/ mabthera; Sait101 (proposed rituximab biosimilar); Standard dose of rituximab; The standard steroid treatment, plasma exchange and rituximab;   D02994   1件: MS4A1   1件: Hematopoietic cell lineage   42件:
11,
13,
14,
17,
35,
36,
43,
44,
45,
46,
49,
50,
51,
52,
53,
56,
60,
61,
63,
64,
65,
66,
83,
84,
85,
86,
93,
94,
96,
97,
162,
222,
223,
229,
256,
271,
283,
284,
285,
288,
300,
331
 83   Salbutamol  5件: Nebulized combination ipratropium bromide with salbutamol; R-salbutamol; R-salbutamol sulphate; Salbutamol; Salbutamol 4mg tablet;   D02147   1件: ADRB2   8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway   13件:
3,
11,
12,
13,
49,
85,
86,
89,
113,
228,
231,
256,
299
 84   Sapropterin  10件: Kuvan® (sapropterin dihydrochloride); Sapropterin; Sapropterin (kuvan); Sapropterin dihydrochloride; Sapropterin dihydrochloride (6r-bh4); Sapropterin dihydrochloride, 6r-bh4, tetrahydrobiopterin; Sapropterin dihydrocholoride; Sapropterin hydrochloride; Sapropterin, sapropterin dihydrochloride; Sapropterin, sapropterin hydrochloride;   D08505   -   -   3件:
86,
124,
240
 85   Saquinavir  2件: Saquinavir; Saquinavir and ritonavir;   D00429
 D01160 
 -   -   2件:
86,
265
 86   Selexipag  4件: I.v. selexipag; Oral selexipag (uptravi); Selexipag; Selexipag (uptravi);   D09994   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   5件:
51,
70,
84,
86,
88
 87   Selonsertib  1件: Selonsertib;   D10988   1件: MAP3K5   12件: Amyotrophic lateral sclerosis (ALS), Apoptosis, Fluid shear stress and atherosclerosis, MAPK signaling pathway, Neurotrophin signaling pathway, Non-alcoholic fatty liver disease (NAFLD), Platinum drug resistance, Protein processing in endoplasmic reticulum, Sphingolipid signaling pathway, TNF signaling pathway, Thermogenesis, Tight junction   1件:
86
 88   Serine  4件: D-serine; D-serine (~2g/day); L-serine; Serine;   D00016   -   -   3件:
2,
6,
86
 89   Sildenafil  25件: 20 mg sildenafil citrate by mouth; 5% sildenafil cream; Access program - sildenafil citrate, viagra, revatio; Acute (1 hour) sildenafil; Bosentan and sildenafil; Era and pde-5i (sildenafil, tadalafil, bosentan, macitentan); Oral sildenafil; Sildenafil; Sildenafil (50 mg); Sildenafil (as citrate); Sildenafil (revatio); Sildenafil (revatio) 20 mg tid; Sildenafil 20 mg tablets; Sildenafil 20mg; Sildenafil 20mg and bosentan 62.5mg; Sildenafil 40mg oral capsule; Sildenafil and losartan; Sildenafil citrate; Sildenafil citrate (uk-92,480); Sildenafil singly or in association with bosentan; Sildenafil therapy; Sitaxsentan and sildenafil; Sodium tanshinone iia sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth; Sub-chronic (4 weeks) sildenafil; Tadalafil and sildenafil;   D02229
 D08514 
 1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   16件:
6,
46,
50,
51,
85,
86,
96,
113,
210,
211,
212,
225,
226,
278,
294,
299
 90   Simvastatin  11件: Encapsulated simvastatin tablets; Ezetimibe+simvastatin drug combination; Simvastatin; Simvastatin 20mg/5ml oral suspension; Simvastatin 40 mg film-coated tablets; Simvastatin 40mg; Simvastatin alternova; Simvastatin susp.; Simvastatin treatment for 28 days; Simvastatin-ratiopharm; Simvastatin-ratiopharm®;   D00434   1件: HMGCR   4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis   19件:
6,
13,
15,
34,
46,
49,
51,
66,
79,
86,
89,
94,
158,
162,
195,
265,
298,
299,
310
 91   Sirolimus  14件: Rapamycin, sirolimus; Sirolimus; Sirolimus (formerly known as rapamycin); Sirolimus 0,1% crème; Sirolimus 0.2%; Sirolimus 0.4%; Sirolimus 2 mg; Sirolimus 2%; Sirolimus and hydroxychloroquine; Sirolimus oral liquid product 1mg/ml; Sirolimus, 2%; Skincerity plus sirolimus/rapamycin; Skinercity plus sirolimus/rapamycin; Topical 0.1% sirolimus;   D00753   1件: MTOR   43件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway   36件:
2,
13,
15,
17,
34,
35,
36,
46,
49,
51,
60,
61,
62,
63,
65,
66,
67,
85,
86,
89,
96,
98,
137,
157,
158,
192,
222,
256,
277,
278,
279,
280,
281,
283,
285,
331
 92   Sitaxentan  2件: Sitaxentan; Sitaxentan sodium;   D07171   1件: EDNRA   7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   1件:
86
 93   Sodium chloride  14件: 0.9% sodium chloride; 0.9% sodium chloride (normal saline); 0.9% sodium chloride injection; 0.9% w/v sodium chloride solution; Isotonic sodium chloride solution; Physiological serum (sodium chloride); Sodium chloride; Sodium chloride (7%); Sodium chloride 0,9%; Sodium chloride 6%; Sodium chloride solution; Sodium chloride solution 0.9%; Sodium chloride solvent; Sodium pyruvate in 0.9% sodium chloride solution;   D02056   -   -   19件:
6,
11,
13,
14,
17,
34,
46,
51,
53,
67,
78,
86,
97,
168,
193,
227,
228,
288,
299
 94   Sorafenib  3件: Nexavar (bay 43-9006) (sorafenib); Sorafenib; Sorafenib (as tosylate);   D06272
 D08524 
 8件: BRAF, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET   83件: Acute myeloid leukemia, Alcoholism, Apelin signaling pathway, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bladder cancer, Breast cancer, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Central carbon metabolism in cancer, Chemokine signaling pathway, Choline metabolism in cancer, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Non-small cell lung cancer, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, VEGF signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway   2件:
34,
86
 95   Sotatercept  2件: Sotatercept; Sotatercept with prednisone boost;   D09670   1件: ACVR2A   4件: Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Signaling pathways regulating pluripotency of stem cells, TGF-beta signaling pathway   2件:
86,
284
 96   Spironolactone  4件: Ambrisentan plus spironolactone; Spironolactone; Spironolactone and conivaptan; Spironolactone captopril carvedilol;   D00443   1件: NR3C2   1件: Aldosterone-regulated sodium reabsorption   6件:
58,
67,
86,
113,
218,
225
 97   Sulfate ion  -  -   -   -   22件:
2,
6,
11,
13,
26,
34,
36,
46,
49,
60,
61,
64,
66,
79,
86,
96,
222,
226,
265,
296,
297,
299
 98   Tacrolimus  13件: Busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf; Interferon beta-1b and tacrolimus; Lcp-tacro (tacrolimus); Non-mtx dmards (e.g. sulfasalazine, leflunomide, bucillamine, tacrolimus, or mizoribin); Rectal tacrolimus; Tacrolimus; Tacrolimus (prograf®); Tacrolimus and mmf; Tacrolimus capsule; Tacrolimus capsules; Tacrolimus combined with prednisone; Tacrolimus prolonged-release hard capsules; Tacrolimus with methotrexate;   D00107
 D08556 
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2   30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway   30件:
2,
11,
13,
36,
46,
49,
50,
51,
53,
60,
61,
62,
65,
66,
85,
86,
95,
96,
97,
113,
151,
158,
164,
222,
224,
226,
228,
283,
284,
299
 99   Tadalafil  11件: Era and pde-5i (sildenafil, tadalafil, bosentan, macitentan); Fdc macitentan/tadalafil; Tadalafil; Tadalafil 20 mg; Tadalafil 20 mg film-coated tablets; Tadalafil 40 mg; Tadalafil and ambrisentan upfront combination therapy; Tadalafil and sildenafil; Tadalafil oral suspension; Tadalafil, placebo; Tadalafil- tablet or oral suspension;   D02008   1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   6件:
6,
51,
75,
84,
86,
113
 100   Tamoxifen  3件: Tamoxifen; Tamoxifen 40 mg daily for one year; Tamoxifen citrate;   D00966
 D08559 
 2件: ESR1, ESR2   9件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway   4件:
2,
86,
113,
227
 101   Terguride  3件: Terguride; Terguride 0.5 mg tablet; Terguride hydrogenmaleate;   D01348   2件: DRD2, PRL   12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway   2件:
51,
86
 102   Tezosentan  1件: Tezosentan;   -   -   -   1件:
86
 103   Thrombin  1件: Thrombin;   D00090   -   -   2件:
86,
88
 104   Tocilizumab  25件: Abatacept, rituximab or tocilizumab; Corticoids+ tocilizumab 8mg/kg/4 weeks; Decrease tocilizumab, abatacept; Inn-tocilizumab; Intra-articular tocilizumab; Mra (tocilizumab); Mra(tocilizumab); Subcutaneous tocilizumab; Tocilizumab; Tocilizumab (actemra®); Tocilizumab (mra-sc); Tocilizumab + glucocorticoids (gcs); Tocilizumab + methotrexate(mtx); Tocilizumab 162 mg; Tocilizumab 162mg/0.9ml jeringa sc; Tocilizumab [roactemra/actemra]; Tocilizumab [roactemra]; Tocilizumab infusion roacemtra (eu); Tocilizumab injection; Tocilizumab prefilled syringe; Tocilizumab sc; Tocilizumab sc 162 mg/0.9 ml prefilled syringe with safety device (pfs); Tocilizumab treatment; Tocilizumab+methotrexate(mtx); Tocilizumab, abatacept;   D02596   1件: IL6R   11件: Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease (NAFLD), PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor   16件:
2,
13,
40,
41,
43,
46,
50,
51,
53,
54,
55,
86,
107,
266,
271,
331
 105   Treprostinil  31件: Eutonic treprostinil solution; Inhaled dry powder treprostinil (liq861); Inhaled treprostinil; Intravenous treprostinil; Intravenous/subcutaneous treprostinil; Iontophoresis of treprostinil; Liq861 inhaled treprostinil; Oral treprostinil; Oral treprostinil (ut-15c) sustained release tablets; Parenteral remodulin (treprostinil) injection; Rapid dose titration group of subcutaneous treprostinil; Remodulin (treprostinil sodium); Remodulin® (treprostinil) 1 mg/ml solution for infusion; Remodulin® (treprostinil) 10 mg/ml solution for infusion; Remodulin® (treprostinil) 2.5 mg/ml solution for infusion; Remodulin® (treprostinil) 5 mg/ml solution for infusion; Slow dose titration group of subcutaneous treprostinil; Subcutaneous treprostinil; Treprostinil; Treprostinil diethanolamine; Treprostinil diolamine; Treprostinil inhalation powder; Treprostinil inhalations; Treprostinil injectable product; Treprostinil sodium; Treprostinil sodium for inhalation; Treprostinil sodium solution for inhalation; Treprostinil sodium, ut-15; Treprostinil, ut-15, lrx-15, 15au81, bw a15au, u-62, 840; Ut-15c (treprostinil diethanolamine); Ut-15c sr (treprostinil diethanolamine);   D06213   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   5件:
51,
84,
85,
86,
88
 106   Trimetazidine  3件: Trimetazidine; Trimetazidine dihydrochloride; Trimetazidine dihydrochloride 20mg;   D01606
 D08642 
 -   -   2件:
58,
86
 107   Tyrosine  2件: L-tyrosine; Tyrosine;   D00022   -   -   3件:
6,
86,
111
 108   Ubenimex  1件: Ubenimex;   D00087   1件: ANPEP   4件: Glutathione metabolism, Hematopoietic cell lineage, Metabolic pathways, Renin-angiotensin system   1件:
86
 109   Ubidecarenone  -  D01065   -   -   12件:
2,
5,
6,
8,
10,
46,
57,
86,
113,
193,
214,
215
 110   Udenafil  1件: Udenafil;   D10027   1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   1件:
86
 111   Vardenafil  2件: Vardenafil; Vardenafil (hidrocloride);   D02731
 D03260
 D08668 
 1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   3件:
13,
86,
299
 112   Zamicastat  1件: Zamicastat;   -   -   -   1件:
86
 113   Zinc acetate  3件: Zinc acetate; Zinc acetate (20mg/d); Zinc acetate dihydrate;   D06408   -   -   7件:
49,
51,
70,
86,
171,
256,
299

先頭へ